A new toolkit for studying how ‘PARP’ activity boosts cancers
A new method developed by scientists at Johns Hopkins Bloomberg School of Public Health is likely to speed the study of an important biological process called ADP-ribosylation. ADP-ribosylation occurs at high levels in some cancers, and drugs called PARP inhibitors, which block ADP-ribosylation, comprise one of the most promising new classes of cancer therapy. Yet…